abbvie stock forecast 2030 abbvie stock forecast 2030

Get 30 Days of MarketBeat All Access Free, Sign in to your free account to enjoy these benefits. I will conclude this analysis by stating that, based on all available information, market headwinds and tailwinds, competitors, and opportunities via its products and pipeline, I still consider AbbVie to be a strong investment opportunity. You should never invest money you cannot afford to lose. My calculation is that Humira revenues in 2023 will be 80% of the 2022 figure, or $16.7bn. And we remain confident in our ability to achieve total sales of more than $9 billion by 2029. If you have an ad-blocker enabled you may be blocked from proceeding. contact@marketbeat.com Thus, it is likely that ABBV will continue to find support on the dips in this type of market environment.. I take the total revenue figure from each year and plug it into an income statement forecast as follows: AbbVie income statement forecast. Read our dividend analysis for ABBV. Migraine therapy Ubrelvy is a future blockbuster, Gonzalez believes, as is Qulipta, in the same indication. The difference between trading assets and CFDs. According to analysts' consensus price target of $161.12, AbbVie has a forecasted upside of 3.2% from its current price of $156.06. (844) 978-6257. . View institutional ownership trends. Revance Therapeutics gapped up 54.34% on January 9, and built upon those gains in February. The consensus rating was moderate buy based on 16 analysts ratings, with 10 recommending buy, five hold and sell. I look forward to seeing if Epcoritamab is approved this year, and although there is not a lot else in the near-term pipeline at this time, I also look forward to seeing how other projects may progress, e.g., opportunities in Parkinson's Disease, Alzheimer's and Cystic Fibrosis. All rights reserved. Excluding items, AbbVie earned $3.31 per share, beating estimates of $3.29 . The acquisition expanded AbbVies neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies. What is the dividend yield for AbbVie? I wrote this article myself, and it expresses my own opinions. With no LOEs on the horizon, it is relatively plain sailing for the company ex-Humira, and the performance of Skyrizi and Rinvoq - to date at least - suggests management does have this massive patent cliff covered. American biopharmaceutical company Abbvie (ABBV) has surged nearly 13% year to date (YTD), and 35% year-over-year (YOY), as of 30 June. I had felt this could be an issue for Skyrizi and Rinvoq, given it is rare for a drug to be as dominant as Humira was, but although the level of competition is fierce, both drugs are more than meeting expectations, and with the entire auto-immune market worth as much as $45 - $50bn, it does seem possible that Skyrizi and Rinvoq could one day generate >$20bn revenues between them, as management hopes. On average, analysts rate AbbVie stock as a buy. AbbVie's Q2'22 earnings threw up some positives and negatives for investors to contemplate. Abbvies first quarter 2022 financial results for the quarter ended 31 March revealed that diluted earnings per share (EPS) increased to $2.51 on a generally accepted accounting principles (GAAP) basis, up from $1.99 a year earlier. Gonzalez has vigorously defended AbbVie against accusations of price manipulation, but the company is renowned for pushing drug prices up annually and should its powerful lobbies become less powerful in the face of external pressure, once again, the sector will start to look unattractive for investors. Most stock quote data provided by BATS. Myelofibrosis has proved to be a tricky indication for drug developers and there are no wholly satisfactory solutions on the market at present, therefore if approved I would expect Navitoclax - a drug that AbbVie has been working on for some time - to generate a couple of billion dollars in peak sales. When looking for ABBV stock forecasts, its important to bear in mind that analysts forecasts can be wrong. As we look beyond 2025, we expect combined sales for Skyrizi and Rinvoq to exceed the peak revenues achieved by Humira, which was more than $21 billion. That makes companies like AbbVie generally very attractive to investors although it should be noted that AbbVie carries a very high level of debt which stood at >$60bn as of Q322 - more or less the amount the company paid to acquire Allergan. I have no business relationship with any company whose stock is mentioned in this article. In the past three months, AbbVie insiders have sold more of their company's stock than they have bought. The average analyst rating for AbbVie stock from 34 stock analysts is "Buy". Slide from JPM Conference 2022 presentation. At their peak, according to a slide from AbbVie's presentation at the JPMorgan (JPM), these 2 drugs are expected to generate more revenues than Humira at its peak. It now expects full-year profit in the range of $13.92-$14.12 a share. Venclexta continues to pick up momentum with sales up 16% to >$500m in Q2'22, and I forecast the drug to exceed $3.2bn in revenues by the end of the decade. Other profitable therapies include but are not limited to SKYRIZI for psoriasis, RINVOQ for rheumatoid arthritis and IMBRUVICA and VENCLEXTA for chronic leukemia conditions. Armed with management's detailed guidance and commentary on sales performance of key assets and new product launches, however, I have completed sales projections for AbbVie to 2030, which I will share in this post, highlighting areas of strength and potential weaknesses. Note that analysts ABBV stock forecasts can be wrong. A AbbVie Inc. (NYSE:ABBV) insider lowered their holding by 87% earlier this year, These 2 Dividend Stocks Could Be a Great Addition to Your Income Portfolio, AbbVie Can Write Diversified Growth Story Without Humira, Rest Of The Business Has Strength, Analyst Says, AbbVie (NYSE:ABBV) Receives New Coverage from Analysts at Guggenheim, AbbVie to Present at the Cowen 43rd Annual Health Care Conference, AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ) for the Treatment of Adults with Moderate to Severe Crohn's Disease, AbbVie Highlights Robust Gastroenterology Portfolio with New Analyses and Data in Inflammatory Bowel Diseases at the 18th Congress of European Crohn's and Colitis Organisation (ECCO), 3 Stocks to Buy Right Now That Are Cash Cows, The painfully high price of Humira is patently wrong, AbbVie Inc. (NYSE:ABBV) SVP Sells $4,310,832.64 in Stock, StockNews.com Upgrades AbbVie (NYSE:ABBV) to "Strong-Buy", AbbVie Inc. (NYSE:ABBV) Director Sells $1,505,000.00 in Stock, Azita Saleki-Gerhardt Sells 25,000 Shares of AbbVie Inc. (NYSE:ABBV) Stock, AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need, view top-rated stocks among Wall Street analysts, 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. Since then, however, the stock price has fallen 18% to. Disclosure: I/we have a beneficial long position in the shares of ABBV, BMY either through stock ownership, options, or other derivatives. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. The 21 analysts offering 12-month price forecasts for Abbvie Inc have a median target of 165.00, with a high estimate of 200.00 and a low estimate of 135.00. 580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. I wrote this article myself, and it expresses my own opinions. Shares of ABBV stock can be purchased through any online brokerage account. It . The company has a robust pipeline of new products that are in some stage of clinical trials. Abbvie has a strong pipeline of projects ahead, and has recently received US FDA approval of its ulcerative colitis drug Rinvoq. AbbVie (NYSE:ABBV) pays an annual dividend of $5.92 per share and currently has a dividend yield of 3.83%. You should consider whether you understand how CFDs work and can afford the risks. AbbVie's free cash flow yield is 10.5% compared to 4.3% for Johnson & Johnson . Multidrug Resistant Bacteria Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2030) Published: March 2, 2023 at 2:55 a.m. All Rights Reserved. With the Hughes Optioneering Strategy, youll soon learn that the safest option for new accounts is options themselves! RHHBY vs. ABBV: Which Stock Is the Better Value Option? Net earnings also saw a steep rise to $4.49bn from $3.55bn, while net revenue jumped to $13.54bn from 13.01bn. AbbVie, like its parent Abbot Laboratories, is a well-established dividend growth stock. A major reason behind Abbvies stellar performance amid the ongoing economic crises is the resolution of the companys Humira (adalimumab) litigation with Alvotech in March 2022. Trial results demonstrated an overall response rate of 63% and a median duration of response of 12 months, where 39% of patients had already tried a CAR-T cell therapy. Skyrizi is a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialisation globally. Perhaps this is an example of how ruthless management can be when encountering falling sales, and a warning that not all company divisions are guaranteed to thrive. Both of these assets appear to be doing the job they were intended for - protecting AbbVie's dominance in various auto-immune markets - and now represent ~13% of AbbVie's total revenue generation. The companys operations span 20 countries, treating more than 60 million people and 40 conditions annually. View ABBV analyst ratings or view top-rated stocks. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. AbbVie is a leader in ESG and sustainability. Bringing RGX314 would be a coup for AbbVie although I am forecasting for only $2bn in peak revenues in 2030 as a hedge against the risk that this candidate does not make it to market on safety grounds. 164.71 0.00 0.00%. Since then, ABBV stock has decreased by 3.4% and is now trading at $156.06. According to the algorithm-based forecaster Wallet Investor in its Abbvie stock forecast for 2022, the price could reach $169.852 by the end of December, $199.491 by 2023 and $229.304 by 2024. I have no business relationship with any company whose stock is mentioned in this article. AbbVie income statement forecast (My table and assumptions). AbbVie stock forecast 2022 - 2025 - 2030 with analysis AbbVie stock stood at $162.110000610352 on 2022-03-31. forecast for 2023 is $159.42, forecast for 2024 is $156.65, forecast for 2025 is $139.68, forecast for 2026 is $124.48, As of February 15th, there was short interest totaling 11,710,000 shares, an increase of 13.7% from the January 31st total of 10,300,000 shares. All rights reserved. I am not receiving compensation for it (other than from Seeking Alpha). This would represent an increase of 1.78%. We have also launched Skyrizi for PSA in rheumatology, where we're seeing strong utilization, which is driving accelerated share growth. Johnson & Johnson Free Cash Flow Forecast for 2023 - 2025 - 2030. Disclosure: I/we have a beneficial long position in the shares of BMY, GILD, ABBV either through stock ownership, options, or other derivatives. Insiders that own company stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Carrie C Strom, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Perry C Siatis, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Scott T Reents, Timothy J Richmond and Timothy J Richmond. Neuroscience looks highly promising too, and aesthetics capable of driving some respectable growth driven by old stager Botox. The firm's revenue for the quarter was up 1.6% compared to the same quarter last year. This included an unfavourable impact of $0.08 a share related to acquired in-process research and development (IPR&D) and milestones expenses incurred during the March quarter. $163.64. Always conduct your own due diligence before investing. As well as the stock price gains AbbVie has always paid a handsome dividend - which has increased by 270% since the Pharma's inception, currently paying $1.48 per quarter, for a current yield of 4% - the highest in the large Pharmaceutical sector. If you have an ad-blocker enabled you may be blocked from proceeding. The company projects the U.S. toxin market (where Botox is the top product) will decline by mid-single digits. Top institutional shareholders include Geode Capital Management LLC (1.91%), Morgan Stanley (1.79%), Moneta Group Investment Advisors LLC (1.65%), Price T Rowe Associates Inc. MD (1.15%), Norges Bank (1.06%) and Legal & General Group Plc (0.66%). Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. AbbVie does not have the funds to pursue any large M&A deals, but it does not need to either, given the strength of its pipeline and products. In the past I have written about the high level of competition between major Pharma in the auto-immune space - for example, for Psoriatic Arthritis the list of approved drugs includes Humira, UCB Pharma's Cimzia, Amgen's Enbrel, Johnson & Johnson's (JNJ) Stelara, Eli Lilly's (LLY) Talzt, Novartis' (NVS) Cosentyx and Bristol-Myers Squibb's (BMY) Orencia. As of 2023 February 22, Wednesday current price of ABBV stock is 151.340$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. Abbvie stock price as been showing a rising tendency so we believe that similar market segments were very popular in the given time frame. PMeds are designed not only to target the specific causes of diseases, often at the genetic level, but the patients that are most likely to benefit from them. Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T), Bristol-Myers Squibb (BMY), Wheaton Precious Metals (WPM), Rogers Communications (RCI) and Open Text (OTEX). 16 analysts have issued 12-month price targets for AbbVie's shares. Only 0.08% of the stock of AbbVie is held by insiders. I have speculatively assigned peak sales of $2bn, although it should be noted that success here is far from guaranteed, although if AbbVie did succeed with ABBV916 sales could be 2 or 3x higher than my forecast. Management initially blamed slow take-up post pandemic for the drug's declining sales, but Gonzalez also told JPM Conference attendees that "new competitive entrants has significantly lowered our sales expectations for Imbruvica". For the next year, analysts predict that Free Cash Flow will reach 6.91B - an increase of 1.94%. According to CompaniesMarketCap, the biopharmas market capitalisation stood at $272.38bn, making it the worlds 30th most valuable company. For full year 2022, Abbvie predicted the adjusted diluted EPS guidance range at $14.00 to $14.20 and $13.92 to $14.12. Pessimistic target level: 151.42 Optimistic target level: 154.48 ABBV (ABBV) Monthly Stock Prediction for 2023 Full forecast for 2023 AbbVie forecast for this year On average, they expect the company's stock price to reach $161.12 in the next twelve months. Analysts have tipped the drug to achieve peak sales of $2.75bn, and although the emergence of CAR-T therapies and some concerns around safety - notably cases of cytokine release syndrome ("CRS') - persist, this revenue figure is achievable in my view. I write about Biotech, Pharma and Healthcare stocks and share investment tips. See AbbVie Inc. (ABBV) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. I'm on twitter @edmundingham. Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. It pays a dividend yield of 3.83%, putting its dividend yield in the top 25% of dividend-paying stocks. The Abbvie stock forecast for 2025 had the price at $259.018. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. Nineteen analysts predict that AbbVie's share price will increase in the coming year, reaching $165.00. That is interesting to me as I think it suggests management will need to commercialize more assets if it wants to hit that target. In this post, I will discuss Q2'22 results, as well as the long-term outlook for AbbVie based on the latest information, goals, risks, and financial modeling analysis, to try to establish a target price for AbbVie stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABBV, but not buy additional shares or sell existing shares. AbbVie's success - as its shareholders will doubtless be aware - stems from the runaway success of its immunology drug Humira, which is indicated for a range of autoimmune conditions, including Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn's Disease, Ulcerative Colitis, Hidradenitis Suppurativa and Ankylosing spondylitis. I believe AbbVie is likely 15 - 20% undervalued at current price. Between September 2021 and April 2022, AbbVie stock went on a sensational bull run, gaining 62% and hitting an all-time peak of $174. This represents a $5.92 dividend on an annualized basis and a dividend yield of 3.79%. As a result I have dropped Imbruvica revenues to just over $3.5bn in 2022 and modelled for a CAGR growth of just 1.5% between then and 2030. Moreover, with surging demand, rising investments in research and development, and increasing e-pharmacy channels, the industry is well-positioned for significant growth New research suggests Depakote ingredient could have a new clinical function. Should I buy or sell AbbVie stock right now? Based on our forecasts, a long-term increase is expected, the "ABBV" stock price prognosis for 2028-02-23 is 287.522 USD. The stock projection varied from the low price target of $135 to the high of $200. And with a dividend yield of 4.9%, AbbVie is quite attractive for investors yearning for . In my model I have then reduced revenues by 20% between 2024 - 2026, and then by 10% per annum between 2027 - 2030. AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. If signs point to that happening I will likely be revising my target price upwards again, but I am playing it more conservative as nobody truly knows the scale of losses after the Humira LOE. PEG Ratios above 1 indicate that a company could be overvalued. AbbVie made the bold decision to take on a heavy debt load and bid for Allergan, with the deal being completed in 2020. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. I haven't included Epcoritamab sales in my forecasts this time, but I hope to adjust the table before Q3'22 results are announced. The company reported $3.60 EPS for the quarter, topping the consensus estimate of $3.54 by $0.06. After creating the income statement I prepare the discounted cash flow/EBITDA multiple analysis. What is a Good Dividend Yield? Post-spin, AbbVie emerged as a research-based biopharma that has more than doubled in size. In the next year, analysts expect Free Cash Flow to reach $26.97B - an increase of 58.68%. Our momentum combined with ramping contributions from new products and new indications will drive accelerating revenue and EPS growth through the rest of the year., ABBV has done very well to add to its impressive gains from the past couple of years. Out of the most recent ratings, BMO Capital Markets Gary Nachman raised its price target from $161 to $174 with an outperform rating, while Truist Financial analyst Robyn Karnauskas raised the Abbvie stock prediction from $118 to $135 while raising rating to a buy. The average price target represents a 6.33% change from the last price of $153.90. Different trading strategies will suit different investment goals with short or long-term focus. The company had recorded a $4.7 billion increase in the contingent consideration liability related to Skyrizi last year. I am using a weighted average cost of capital of ~10%, which is broadly consistent with the figure I use when modelling for the other 7 members of what I term the "Big 8" US Pharmas - Johnson & Johnson, Eli Lilly, Pfizer, Merck & Co (MRK), Bristol Myers Squibb, Amgen, and Gilead Sciences (GILD) - which helps prove the accuracy of the calculation. The company employs 50,000 workers across the globe. Today, AbbVie operates as a diversified multi-national pharmaceutical company with a patient-centric approach to research. To see all exchange delays and terms of use please see Barchart's disclaimer. AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV.". Data from two Phase 3 induction studies and one maintenance study supported the approval. As we can see above one of either Skyrizi or Rinvoq has now been approved for all of the same indications as Humira is, except for Hidradenitis Suppurativa, although Rinvoq is undergoing a Phase study in this indication. That is substantially higher than the 12% CAGR achieved between 2018 - 2022, although that period includes the additional revenues from Allergan. Abbvies haematologic oncology portfolio, neuroscience portfolio and aesthetics portfolio reported net revenues of $1.65bn, $1.49bn and $1.37bn, respectively. The official website for the company is www.abbvie.com. There is an element of risk to that as clinical trial failures are common, even for a giant like AbbVie, and even CEO Gonzalez may be forced to backtrack on some of his blockbuster sales projections. Although Wallet Investor did not provide targets for 2030, its longer-term Abbvie stock prediction expected the price to hit $300.386 in June 2027. AbbVie projected sales - immunology (my forecasts and assumptions). These products are not suitable for everyone and you should therefore consider your objectives, financial situation, needs and experience with these products before investing in them. Is this happening to you frequently? The company's average rating score is 2.44, and is based on 7 buy ratings, 9 hold ratings, and no sell ratings. In the last two years, GSK's Free Cash Flow has grown by 0.37%, rising from 6.76B to 6.78B.